Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: F. Hoffmann-La Roche Ltd
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) versus tocilizumab therapy in patients with active rheumatoid arthritis with an incomplete response to methotrexate
To investigate the safety, tolerability and efficacy of rituximab in combination with tocilizumab in patients with active RA despite a stable dose of methotrexate.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Diffuse large B-cell Lymphoma
• To determine the recommended Phase II dose (RP2D) for polatuzumab vedotin (Pola) when given in combination with fixed doses of obinutuzumab (G) and atezolizumab (Atezo) • To evaluate the safety and...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A two-arm, non-randomized, multicenter, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer
To assess the overall safety and tolerability of subcutaneous (SC) trastuzumab in HER2-positive early breast cancer (EBC) patients with assisted administration using a conventional syringe and needle ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
Open label, parallel group, multicenter study of two IV ibandronate regimens (2 mg every 2 months and 3 mg every 3 months) in women with postmenopausal osteoporosis who completed trial BM16550
To study the tolerability and safety (including bone histomorphometry) of long-term treatment with intravenous ibandronate administered as 2 regimens, either 2 mg every 2 months or 3 mg every 3 months...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
Estudio aleatorizado, controlado, abierto, multicéntrico y en grupos paralelos para comparar la eficacia y seguridad de RO0503821 con las de darbepoetina alfa administrado por vía intravenosa en intervalos de administración prolongados para el tratamiento de mantenimiento de la anemia en pacientes con nefropatía crónica en hemodiálisis
Primario: - Comparar la eficacia de RO0503821 administrado por vía intravenosa en intervalos prolongados con la de darbepoetin alfa en el mantenimiento de las concentraciones de hemoglobina en pacient...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A study of the pharmacokinetic and pharmacodynamic activity of rituximab in combination with methotrexate (MTX) in synovial tissue and in peripheral blood of patients with rheumatoid arthritis. Estudio para evaluar la actividad farmacocinética y farmacodinámica de rituximab en combinación con metotrexato (MTX) en tejido sinovial y en sangre periférica de pacientes con artritis reumatoide
1. Investigar el patrón de depleción de células B (CD19+) en tejido sinovial y sangre periférica tras el tratamiento con rituximab (1000 mg iv x 2) en pacientes con AR activa.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone
The primary objective is to determine the efficacy of taspoglutide versus placebo on glycemic control (as assessed by HbA1c) after 24 weeks of treatment, in patients with type 2 diabetes mellitus inad...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
Study to evaluate the safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to platinum-based chemotherapy in patients with metastatic, non-squamous, PD-L1-selected, non-small cell lung cancer that has not been treated with chemotherapy. Estudio para evaluar la seguridad y la eficacia de MPDL3280A (anticuerpo Anti-DP-L1) comparado con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico y no epidermoide metastásico seleccionados por PD-L1 que no han recibido quimioterapia previa
The primary objective for this study is to evaluate the efficacy of MPDL3280A compared with carboplatin or cisplatin + pemetrexed in chemotherapy-naive patients with Stage IV non squamous NSCLC, as me...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
This is a phase II proof of concept study to investigate efficacy, safety and tolerability of 5.0 mg of RO3300074 when administered once daily for 12 months (52 weeks) compared with placebo. The prima...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer
To compare progression-free survival (PFS) based on tumor assessments by an independent review facility (IRF) between patients in the two treatment arms.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
14
15
16
17
18
19
20
21
22
23
Next